Medtech stories we missed this week: Oct. 13, 2017


missed medtech

[Image from]

From Orthocell’s distribution deal to CorNeat unveiling its artificial cornea, here are seven medtech stories we missed this week but thought were still worth mentioning.

1. OrthoCell inks Australian distro deal

Orthocell announced in an Oct. 10 press release that it has signed a distribution deal with Surgical Specialities. The deal will make Surgical Specialities the exclusive distributor in Australia and New Zealand for Orthocell’s cell therapies for tendon regeneration and cartilage regeneration. Surgical Specialties is set to take over distribution responsibilities of the Ortho-ATI and Ortho-ACI systems for the next five years.

2. Viveve wins Taiwanese clearance for Viveve system

Viveve Medical has won regulatory approval in Taiwan for its Viveve System, according to an Oct. 10 press release. The approval allows the company to market their system in Taiwan for general surgical procedures for electrocoagulation and hemostasis.

3. Faxitron wins FDA nod for radiographic imager

Faxitron announced in an Oct. 10 press release that it has won FDA 510(k) clearance for its VersaVision digital imaging system. The imaging system is designed to help create better precision and workflow in clinical settings. It is used for radiographic imaging of core biopsies and surgically excised specimens.

Get the full story on our sister site, MassDevice.

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Speak Your Mind